Antibody-Drug Conjugates in Bladder Cancer

被引：32

作者：

Vlachostergios, Panagiotis J. ^{[1
]}

Jakubowski, Christopher D. ^{[1
]}

Niaz, Muhammad J. ^{[1
]}

Lee, Aileen ^{[1
]}

Thomas, Charlene ^{[1
]}

Hackett, Amy L. ^{[1
]}

Patel, Priyanka ^{[1
]}

Rashid, Naureen ^{[1
]}

Tagawa, Scott T. ^{[1
,2
,3
]}

机构：

[1] Weill Cornell Med, Div Hematol & Med Oncol, New York, NY USA

[2] Weill Cornell Med, Meyer Canc Ctr, New York, NY USA

[3] Weill Cornell Med, Dept Urol, New York, NY USA

来源：

BLADDER CANCER | 2018年 / 4卷 / 03期

关键词：

Antibody-drug conjugate; urothelial carcinoma; bladder cancer; targeted therapy; METASTATIC UROTHELIAL CARCINOMA; MONOCLONAL-ANTIBODY; PHASE-I; SACITUZUMAB GOVITECAN; GEMTUZUMAB OZOGAMICIN; TRASTUZUMAB EMTANSINE; BRENTUXIMAB VEDOTIN; MEMBRANE ANTIGEN; PSMA EXPRESSION; SOLID TUMORS;

D O I：

10.3233/BLC-180169

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Urothelial carcinoma (UC) is characterized by expression of a plethora of cell surface antigens, thus offering opportunities for specific therapeutic targeting with use of antibody-drug conjugates (ADCs). ADCs are structured from two major constituents, a monoclonal antibody (mAb) against a specific target and a cytotoxic drug connected via a linker molecule. Several ADCs are developed against different UC surface markers, but the ones at most advanced stages of development include sacituzumab govitecan (IMMU-132), enfortumab vedotin (ASG-22CE/ASG-22ME), ASG-15ME for advanced UC, and oportuzumab monatox (VB4-845) for early UC. Several new targets are identified and utilized for novel or existing ADC testing. The most promising ones include human epidermal growth factor receptor 2 (HER2) and members of the fibroblast growth factor receptor axis (FGF/FGFR). Positive preclinical and early clinical results are reported in many cases, thus the next step involves further improving efficacy and reducing toxicity as well as testing combination strategies with approved agents.

引用

页码：247 / 259

页数：13

共 86 条

[1] Circulating tumor cells in patients with advanced urothelial carcinoma of the bladder: Association with tumor stage, lymph node metastases, FDG-PET findings, and survival [J].

Abrahamsson, Johan ;

Aaltonen, Kristina ;

Engilbertsson, Helgi ;

Liedberg, Fredrik ;

Patschan, Oliver ;

Ryden, Lisa ;

Sjodahl, Gottfrid ;

Gudjonsson, Sigurdur .

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2017, 35 (10) :606.e9-606.e16

[2]

*ADC REV, 2017, ADC REV

[3]

*ADC REV, 2018, ADC REV

[4]

ADC Review, 2016, ADC REV

[5]

[Anonymous], 2017, Cancer Discov, V7, pOF3, DOI [10.1158/2159-8290.CD-NB2017-043, 10.1158/2159-8290.CD-NB2016-159]

[6]

[Anonymous], J CLIN ONCOL S

[7] Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study [J].

Apolo, Andrea B. ;

Infante, Jeffrey R. ;

Balmanoukian, Ani ;

Patel, Manish R. ;

Wang, Ding ;

Kelly, Karen ;

Mega, Anthony E. ;

Britten, Carolyn D. ;

Ravaud, Alain ;

Mita, Alain C. ;

Safran, Howard ;

Stinchcombe, Thomas E. ;

Srdanov, Marko ;

Gelb, Arnold B. ;

Schlichting, Michael ;

Chin, Kevin ;

Gulley, James L. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (19) :2117-+

[8] Human SLITRK family genes: genomic organization and expression profiling in normal brain and brain tumor tissue [J].

Aruga, J ;

Yokota, N ;

Mikoshiba, K .

GENE, 2003, 315 :87-94

[9] The trophoblast cell surface antigen 2 and miR-125b axis in urothelial bladder cancer [J].

Avellini, Chiara ;

Licini, Caterina ;

Lazzarini, Raffaella ;

Gesuita, Rosaria ;

Guerra, Emanuela ;

Tossetta, Giovanni ;

Castellucci, Clara ;

Giannubilo, Stefano Raffaele ;

Procopio, Antonio ;

Alberti, Saverio ;

Mazzucchelli, Roberta ;

Olivieri, Fabiola ;

Marzioni, Daniela .

ONCOTARGET, 2017, 8 (35) :58642-58653

[10] Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial [J].

Balar, Arjun V. ;

Galsky, Matthew D. ;

Rosenberg, Jonathan E. ;

Powles, Thomas ;

Petrylak, Daniel P. ;

Bellmunt, Joaquim ;

Loriot, Yohann ;

Necchi, Andrea ;

Hoffman-Censits, Jean ;

Perez-Gracia, Jose Luis ;

Dawson, Nancy A. ;

van der Heijden, Michiel S. ;

Dreicer, Robert ;

Srinivas, Sandy ;

Retz, Margitta M. ;

Joseph, Richard W. ;

Drakaki, Alexandra ;

Vaishampayan, Ulka N. ;

Sridhar, Srikala S. ;

Quinn, David I. ;

Duran, Ignacio ;

Shaffer, David R. ;

Eigl, Bernhard J. ;

Grivas, Petros D. ;

Yu, Evan Y. ;

Li, Shi ;

Kadel, Edward E., III ;

Boyd, Zachary ;

Bourgon, Richard ;

Hegde, Priti S. ;

Mariathasan, Sanjeev ;

Thastrom, AnnChristine ;

Abidoye, Oyewale O. ;

Fine, Gregg D. ;

Bajorin, Dean F. .

LANCET, 2017, 389 (10064) :67-76

← 1 2 3 4 5 6 7 8 9 →